Table 2. Behavioral and Physiological Measures per Treatment Group.

		Baseline				Follow-up
	RG		ADHD		RG		ADHD
	Placebo	Active	Placebo	Active	Placebo	Active	Placebo	Active
Behavior, mean (SD)
CBCL ADHDa	1.9 (2.1)	2.1 (2.3)	9.0 (3.1)	8.8 (2.1)	2.5 (2.3)	1.8 (1.6)	10.1 (2.2)	7.6 (3.5)
CBCL Attention Problems	2.7 (2.8)	2.5 (3.6)	8.9 (3.5)	9.1 (2.5)	3.4 (2.8)b	2.4 (2.6)b	10.5 (3.3)b	7.7 (3.0)b
CBCL Rule Breaking	1.4 (2.2)	0.7 (0.9)	3.8 (2.3)	3.1 (2.8)	1.0 (1.5)	1.2 (1.8)	4.1 (2.4)	2.4 (1.9)
CBCL Aggressive Behavior	2.2 (3.7)	2.2 (2.7)	11.0 (5.8)	9.7 (7.2)	1.8 (3.1)	2.7 (3.2)	11.8 (5.4)	7.8 (3.5)
Physiology, mean (SD)
%DHA (C22:6 n-3)c	0.58 (0.23)	0.54 (0.24)	0.67 (0.19)	0.49 (0.13)	0.48 (0.19)d	0.68 (0.24)d	0.54 (0.15)d	0.67 (0.27)d
Urine samples HVAe	1.4 (0.2)	1.4 (0.3)	1.5 (0.3)	1.5 (0.4)	1.3 (0.2)	1.3 (0.3)	1.4 (0.3)	1.5 (0.3)
EFAQf	1.3 (2.3)	0.9 (1.8)	1.8 (1.7)	1.8 (2.1)	1.3 (2.3)	0.5 (0.9)	1.6 (2.0)	1.8 (1.7)

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; CBCL, Child Behavior Checklist; DHA, docosahexaenoic acid; EFAQ, Essential Fatty Acids Questionnaire; HVA, homovanillic acid; RG, reference group of typically developing children.

^aRG^placebo: 1 baseline, 2 follow-up; RG^active: 2 follow-up; ADHD^active: 1 baseline, 6 follow-up.

^bMain effect of diagnosis and treatment group at follow-up (ANCOVA and LME: p≤0.001).

^cRG^placebo: 1 baseline, 2 follow-up; RG^active: 1 baseline, 2 follow-up; ADHD^placebo: 3 baseline, 1 follow-up; ADHD^active: 1 baseline, 2 follow-up, 1 both (missing data).

^dMain effect of treatment group at follow-up (ANCOVA and LME: p<0.001).

^eRG^placebo: 2 follow-up; RG^active: 1 baseline, 2 follow-up; ADHD^active: 1 baseline, 2 follow-up (missing data).

^fRG^placebo: 2 follow-up; RG^active: 1 follow-up; ADHD^active: 1 baseline, 1 follow-up (missing data).